357426-13-2

Basic information

• Product Name: 1,3,4,5-Tetrahydro-1,5-methano-2H-3-benzazepin-2-one
• Synonyms: 1,3,4,5-Tetrahydro-1,5-methano-2H-3-benzazepin-2-one;1,5-Methano-2H-3-benzazepin-2-one, 1,3,4,5-tetrahydro-;4,5-Dihydro-1H-1,5-Methanobenzo[d]azepin-2(3H)-one;1,5-Methano-2-oxo-2,3,4,5-tetrahydro-1H-3-benzazepine
• CAS NO: 357426-13-2
• Molecular Formula: C11H11NO
• Molecular Weight: 173.214
• Mol File: 357426-13-2.mol

Chemical Properties

• Boiling Point: 397.897°C at 760 mmHg
• Flash Point: 234.426°C
• Appearance: /
• Density: 1.192g/cm³
• Vapor Pressure: 0mmHg at 25°C
• Refractive Index: 1.592
• CAS DataBase Reference: 1,3,4,5-Tetrahydro-1,5-methano-2H-3-benzazepin-2-one(CAS DataBase Reference)
• NIST Chemistry Reference: 1,3,4,5-Tetrahydro-1,5-methano-2H-3-benzazepin-2-one(357426-13-2)
• EPA Substance Registry System: 1,3,4,5-Tetrahydro-1,5-methano-2H-3-benzazepin-2-one(357426-13-2)

Safety Data

• Hazardous Substances Data: 357426-13-2(Hazardous Substances Data)

Usage

Uses

Since the provided materials do not specify the uses of 1,3,4,5-Tetrahydro-1,5-methano-2H-3-benzazepin-2-one, it is not possible to list its applications based on the given information. However, based on the general properties of benzazepines, potential uses in various industries could include:
Used in Pharmaceutical Industry:
1,3,4,5-Tetrahydro-1,5-methano-2H-3-benzazepin-2-one could be used as a pharmaceutical intermediate or a lead compound for the development of new drugs, given its unique chemical structure and the potential for interaction with biological targets.
Used in Chemical Research:
As a member of the benzazepine class, 1,3,4,5-Tetrahydro-1,5-methano-2H-3-benzazepin-2-one could be used in chemical research to study the properties and reactions of benzazepines, contributing to the understanding of this class of compounds and their potential applications.
Used in Material Science:
Depending on its physical and chemical properties, 1,3,4,5-Tetrahydro-1,5-methano-2H-3-benzazepin-2-one might be explored for use in the development of new materials with specific characteristics, such as in polymers or other advanced materials.

InChI:InChI=1/C11H11NO/c13-11-10-5-7(6-12-11)8-3-1-2-4-9(8)10/h1-4,7,10H,5-6H2,(H,12,13)

Upstream product

• 357426-12-1 methyl 3-(aminomethyl)indan-1-carboxylate 
• 2856-63-5 2-Chlorophenylacetonitrile 
• 19472-74-3 2-(2-bromophenyl)acetonitrile 
• 29427-70-1 methyl 3-oxo-2,3-dihydro-1H-indene-1-carboxylate 
• 29427-69-8 3-oxoindan-1-carboxylic acid 
• 357426-11-0 methyl 3-cyano-3-(trimethylsilanyloxy)indan-1-carboxylate 
• 474024-38-9 3-[1,3]dioxolan-2-ylidene-3H-indene-1-carbonitrile 

Downstream Products

• 357425-93-5 1,5-methano-2,3,4,5-tetrahydro-1H-3-benzazepine p-toluenesulfonic acid salt 

Relevant articles and documents

Synthesis of (1-(aminomethyl)-2,3-dihydro-1H-inden-3-yl)methanol: Structural confirmation of the main band impurity found in Varenicline starting material

Described here is the synthesis of (1-(aminomethyl)-2,3-dihydro-1H-inden-3- yl)methanol 1, the previously unidentified impurity found in the synthesis of 2,1 providing a confirmation of the structure. Fabbrica Italiano Sintetici (FIS), working in conjunction with Pfizer Groton, reported an unidentified impurity, referred to as the "main band impurity", in 2 at levels of 0.4 to 0.8%. The structure was postulated to be 1, the open-ring product of the lithium aluminum hydride (LAH) reduction of 3 to 2. Although the cis isomer of 1 was previously reported in the literature,2 a much shorter racemic synthesis was developed using intermediates employed for the production of Varenicline. Several reducing agents were screened for the synthesis of 1, with LiAlH4 followed by basic workup conditions giving optimal results. High performance liquid chromatography (HPLC) analysis ultimately confirmed the structure of 1 as the main band impurity generated during the synthesis of 2. Copyright Taylor & Francis Group, LLC.

Preparation of 1,5-methano-2,3,4,5-tetrahydro-1H-3-benzazepine via Pd-catalyzed cyclization

(Equation Presented) A new approach to prepare 1,5-methano-2,3,4,5- tetrahydro-1H-3-benzanepine (1) is discussed. This strategy utilized a tandem Michael addition and Pd-catalyzed cyclization to afford cyanobenzofulvene acetal 13. This indene intermediate

PROCESS FOR THE PREPARATION OF ARYL FUSED POLYCYCLIC LACTAMS

A process for the preparation of aryl fused polycyclic lactams of formulaI which are useful intermediates in the synthesis of aryl fused azapolycyclic compounds as agents for the treatment of neurological and psychological disorders.

A general route to the synthesis of 1,5-methano- and 1,5-ethano-2, 3,4,5-tetrahydro-1h-3-benzazepines

A general approach to preparing 1,5-methano-(1) and l,5-ethano-2,3,4,5- tetrahydro-lff-3-benzazepine (2) is discussed. This strategy involves converting an indanone or tetralone (4) to a cyanohydrin (3) which is subjected to hydrogenolysis followed by lac

Process for the preparation of 1,3-substituted indenes and aryl-fused azapolycyclic componunds

The present invention relates to processes for the preparation of any of the intermediate 1,3-substituted indenes of the formulae (Ia), (Ib) and (Ic) or a mixture thereof: wherein R1, R2, R3, R4, and R5 are defined herein. Compounds of formulae (Ia), (Ib) and (IC) or mixtures thereof are useful in the preparation of compounds of formula (II): wherein R2, R3 and R6 are also defined herein.

Aryl fused azapolycyclic compounds

Compounds of the formula and their pharmaceutically acceptable salts, wherein R1, R2, and R3are as defined herein; intermediates for the synthesis of such compounds, pharmaceutical compositions containing such compounds; a